{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T17:33:02Z","timestamp":1772040782934,"version":"3.50.1"},"reference-count":25,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2010,7,15]],"date-time":"2010-07-15T00:00:00Z","timestamp":1279152000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2010,11]]},"abstract":"<jats:sec><jats:label\/><jats:p> <jats:bold>WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT<\/jats:bold> <\/jats:p><jats:p>\u2022\u2003Drug\u2010induced hepatic injury is one of the most important reasons for drug withdrawal in adults.<\/jats:p><jats:p>\u2022\u2003Very little is known about drug\u2010induced hepatic injury in children and adolescents.<\/jats:p><jats:p> <jats:bold>WHAT THIS STUDY ADDS<\/jats:bold> <\/jats:p><jats:p>\u2022\u2003The rate of hepatic injury as suspected adverse drug reactions in the paediatric population is low.<\/jats:p><jats:p>\u2022\u2003Drugs associated with hepatotoxicity in children and adolescents were mostly known to be associated with hepatotoxicity in adults as well.<\/jats:p><\/jats:sec><jats:sec><jats:title>AIM<\/jats:title><jats:p>To identify which drugs are associated with reports of suspected hepatic injury in children and adolescents.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Using a worldwide pharmacovigilance database, VigiBase, we conducted a case\/non\u2010case study on suspected adverse drug reactions (ADRs) occurring in the population &lt;18 years old. Cases were all the records with hepatic ADRs and non\u2010cases were all the other ADR records. Records regarding topically administered drugs were excluded from both groups. The association between drug and suspected hepatic ADRs was calculated using the reporting odds ratio (ROR) as a measure of disproportionality while adjusting for gender, country, reporter and calendar year. Sub\u2010analyses were performed within therapeutic class and by excluding vaccination\u2010related reports to reduce confounding.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Overall, 6595 (1%) out of 624\u2003673 ADR records in children and adolescents concerned hepatic injury. Most of the reported hepatic injuries concerned children 12\u201317 years of age. Drugs that were most frequently reported as suspected cause and were associated with hepatic injury comprised paracetamol, valproic acid, carbamazepine, methotrexate, minocycline, zidovudine, pemoline, ceftriaxone, bosentan, ciclosporin, atomoxetine, olanzapine, basiliximab, erythromycin and voriconazole. The association between hepatotoxicity and all these drugs, except for basiliximab, is already known.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Drug\u2010induced hepatic injury is infrequently reported (only 1% of total) as a suspected ADR in children and adolescents. The drugs associated with reported hepatotoxicity (paracetamol, antiepileptic and anti\u2010tuberculosis agents) are known to be hepatotoxic in adults as well, but age related changes in associations were observed. VigiBase is useful as a start to plan further drug safety studies in children.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2125.2010.03754.x","type":"journal-article","created":{"date-parts":[[2010,7,15]],"date-time":"2010-07-15T20:57:53Z","timestamp":1279227473000},"page":"721-728","source":"Crossref","is-referenced-by-count":51,"title":["Drug\u2010induced hepatic injury in children: a case\/non\u2010case study of suspected adverse drug reactions in VigiBase"],"prefix":"10.1111","volume":"70","author":[{"given":"Carmen","family":"Ferrajolo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"Capuano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katia M. C.","family":"Verhamme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martijn","family":"Schuemie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno H.","family":"Stricker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam C. J. M.","family":"Sturkenboom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,7,15]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra021844"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01388.x"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(03)00030-9"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2008.02.005"},{"key":"e_1_2_8_6_2","first-page":"3","volume-title":"Liver Disease in Children","author":"Karpen S","year":"2001"},{"key":"e_1_2_8_7_2","unstructured":"DavisPJ.Pharmacology for infants and children.Review course lectures during the 80th Conference of International Anesthesia Research Society (IARS) 2006."},{"key":"e_1_2_8_8_2","unstructured":"LindquistM.The WHO adverse reaction database: basic facts. Uppsala: Uppsala Monitoring Centre;2004. Available athttp:\/\/www.who\u2010umc.org\/graphics\/4789.pdf(last accessed 23 January 2010)."},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200427120-00003"},{"key":"e_1_2_8_10_2","unstructured":"The adverse event reporting system (AERS). Available athttp:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Surveillance\/AdverseDrugEffects\/default.htm(last accessed 20 August 2009)."},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10618-006-0052-8"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200528110-00002"},{"key":"e_1_2_8_13_2","unstructured":"The Uppsala Monitoring Centre.Report from the WHO Collaborating Centre for International Drug Monitoring: WHO Collaborating Centre for International Drug Monitoring.2009. Available athttp:\/\/www.who\u2010umc.org\/graphics\/21411.pdf(last accessed 12 December 2009)."},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1997.00615.x"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.668"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(92)90158-J"},{"key":"e_1_2_8_17_2","volume-title":"Drug\u2010Induced Hepatic Injury","author":"Stricker BH","year":"1992"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1001"},{"key":"e_1_2_8_19_2","unstructured":"MICROMEDEX\u00ae 1.0 healthcare series. Available athttp:\/\/www.thomsonhc.com\/home\/dispatch(last accessed 7 September 2009).2008."},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.a2245"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2005.12.051"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.104.4.e39"},{"key":"e_1_2_8_23_2","volume-title":"Liver Disease in Children","author":"Suchy FJ","year":"2001"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.113.S3.1097"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.2007.00552.x"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1157"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2010.03754.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2010.03754.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T10:22:58Z","timestamp":1697451778000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2010.03754.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,15]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["10.1111\/j.1365-2125.2010.03754.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03754.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,15]]}}}